(secondQuint)A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD.

 This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week study, consisting of 3 distinct periods: a screening period, pretreatment period, and treatment period.

 The study will enroll patients who have GERD and continue to experience GERD symptoms while receiving QD, standard-dose PPI therapy.

 Eligible patients will continue to take their PPI and will be randomized to placebo or to one of three doses of study drug.

.

 A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD@highlight

The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to patients who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose PPIs